Covid19 Clinical Trial
— DW-MSCOfficial title:
Therapeutic Study to Evaluate the Safety and Efficacy of DW-MSC in COVID-19 Patients: Randomized, Double-blind, and Placebo-controlled
Verified date | January 2021 |
Source | Ina-Respond |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a phase 1 clinical trial to verify the safety and efficacy of DW-MSC in COVID-19 patients. A total of 9 subjects are randomly allocated. Subjects who meet the final inclusion and exclusion criteria are randomized to the test groups (low-dose group and high-dose group) or control group (placebo group) in a ratio of 1:1:1. Subjects assigned to the test groups were administered intravenously once with 5 x 10^7cells of DW-MSC for the low-dose group or 1 x 10^8cells for the high-dose group after registration. Subjects assigned to the control group were administered with placebo in the same manner as the test drug (DW-MSC). At this time, all of the existing standard co-treatment are allowed. DW-MSC is adjunct therapy to standard therapy. This clinical trial is a double-blind trial, in which a randomized method will be used. To maintain the double-blindness of the study, statistician who do not participate in this study independently generate randomization code. Subjects will be randomized to the test groups (low-dose group and high-dose group) or the control group (placebo group) in a 1:1:1 ratio. After the completion of the trial, the randomization code will be disclosed after unlocking the database and unblinding procedures. Follow Up period: observed for 28 days after a single administration
Status | Completed |
Enrollment | 9 |
Est. completion date | January 14, 2021 |
Est. primary completion date | January 14, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 19 Years and older |
Eligibility | Inclusion Criteria: 1. Age of 19 years or older at the time of screening 2. Those who have been confirmed COVID-19 infection through PCR test 3. Patients with mild or moderate COVID-19 who meet National EWS (0~6) 4. Those who have given written consent and voluntarily decided to participate before the screening procedure after understanding the detailed description of the clinical trial. 5. Those who are suitable as subjects for this clinical study when judged by physical examination, clinical laboratory test, and other medical examination as stated in the flowchart of protocol. Exclusion Criteria: 1. Those who have history of hypersensitivity to the components of the investigational product or the reference product 2. Those with viral or bacterial pneumonia other than expected indications 3. Patients receiving organ transplants within 6 months of screening 4. Patients with a history of pulmonary embolism 5. Patients who have indications of investigational products as an underlying disease (ex. HIV patients in the clinical study of antiretroviral drugs) 6. Patients who are pregnant or lactating 7. Those who are determined by the investigator to be unsuitable for participation in the clinical trial due to other reasons including the results of the clinical laboratory test. 8. Patients participating in other clinical studies |
Country | Name | City | State |
---|---|---|---|
Indonesia | Site 550: University of Hassanudin/ Dr. Wahidin Sudirohusodo Hospital | Makassar |
Lead Sponsor | Collaborator |
---|---|
Ina-Respond | Daewoong Pharmaceutical Co. LTD., National Institute of Health Research and Development, Ministry of Health Republic of Indonesia |
Indonesia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of TEAE* in Treatment group | Incidence of TEAE* in Treatment group
* TEAE: Treatment-Emergent Adverse Event All adverse reactions will be organized according to System Organ Class (SOC) and Preferred Term (PT) using MedDRA (Medical Dictionary for Regulatory Activities), and the incidence of treatment-emergent adverse events will be summarized for the coded adverse reactions. |
28 days | |
Secondary | Survival rate | Survival rate is defined as the rate of subjects surviving until Day 14 and Day 28, and the number and rate of surviving subjects for each administration group is given. | until Day 14 and Day 28 | |
Secondary | Duration of hospitalization | Duration of hospitalization is defined as the number of days in the hospital until Day 28, and descriptive statistics (number of subjects, mean, standard deviation, median, minimum, maximum) are given for each administration group. | 28 days | |
Secondary | Clinical improvement Ordinal scale | Clinical improvement measured by Ordinal scale change for clinical improvement from baseline to Day 14 and 28 | from baseline to Day 14 and Day 28 | |
Secondary | Clinical improvement National EWS | Clinical improvement measured by National EWS (National Early Warning Score) change from baseline to Day 7, 14, 28.
EWS Points, Risk and Interpretation as follows: 0~4: Low clinical risk; interpretation= Ward-based response 3~4 : Low~medium clinical risk; interpretation= Urgent ward-based response 5~6: Medium clinical risk; interpretation= Key threshold for urgent response |
from baseline to Day 7, 14 and Day 28 | |
Secondary | Clinical improvement Oxygenation index | Clinical improvement measured by Oxygenation index (PaO2/FiO2) change from baseline (Day 1, 3, 7, 10, 14, 28) | Day 1, 3, 7, 10, 14, 28 | |
Secondary | Clinical improvement Lung involvement change | Clinical improvement measured by Lung involvement change by Imaging from baseline (Day 7, 14, 28) | Day 7, 14, 28 | |
Secondary | Clinical improvement Inflammation markers change | Inflammation markers change from baseline for WBC | Day 7, 14, 28 | |
Secondary | Clinical improvement Inflammation markers change | Inflammation markers change from baseline for Lymphocytes | Day 7, 14, 28 | |
Secondary | Clinical improvement Inflammation markers change | Inflammation markers change from baseline for ESR | Day 7, 14, 28 | |
Secondary | Clinical improvement Inflammation markers change | Inflammation markers change from baseline for CRP | Day 7, 14, 28 | |
Secondary | Clinical improvement Inflammation markers change | Inflammation markers change from baseline for Fibrinogen | Day 7, 14, 28 | |
Secondary | Clinical improvement Inflammation markers change | Inflammation markers change from baseline for IL-6, TNF-a, IL-1ß, IF-? (Day 7, 14, 28) | Day 7, 14, 28 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05047692 -
Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04395768 -
International ALLIANCE Study of Therapies to Prevent Progression of COVID-19
|
Phase 2 | |
Completed |
NCT04506268 -
COVID-19 SAFE Enrollment
|
N/A | |
Terminated |
NCT04555096 -
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
|
Phase 2 | |
Completed |
NCT04508777 -
COVID SAFE: COVID-19 Screening Assessment for Exposure
|
||
Completed |
NCT04961541 -
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04546737 -
Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients
|
N/A | |
Terminated |
NCT04581915 -
PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT04543006 -
Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19
|
N/A | |
Terminated |
NCT04542993 -
Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy
|
Phase 2 | |
Completed |
NCT04494646 -
BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)
|
Phase 2 | |
Completed |
NCT04532294 -
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants
|
Phase 1 | |
Completed |
NCT04387292 -
Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT04537663 -
Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults
|
Phase 4 | |
Not yet recruiting |
NCT04527211 -
Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel
|
Phase 3 | |
Not yet recruiting |
NCT05038449 -
Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19
|
N/A | |
Completed |
NCT04979858 -
Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask
|
N/A | |
Completed |
NCT04610502 -
Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients
|
Phase 2 | |
Active, not recruiting |
NCT06042855 -
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)
|
Phase 3 |